A new TNM classification is better than ISS at predicting survival in stage III unresectable non-small cell lung cancer (NSCLC). A study by the European lung cancer working party (ELCWP)
T. Berghmans, J. J. Lafitte, J. Thiriaux, P. Van Houtte, J. Lecomte, A. Efremidis, V. Giner, M. Paesmans, J. Klastersky, J. P. Sculier (Bruxelles, Charleroi, Belgium; Lille, France; Athens, Greece; Valence, Spain)
Source: Annual Congress 2003 - Lung cancer staging and combined modality treatment
Session: Lung cancer staging and combined modality treatment
Session type: Oral Presentation
Number: 1076
Disease area: Thoracic oncology
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Berghmans, J. J. Lafitte, J. Thiriaux, P. Van Houtte, J. Lecomte, A. Efremidis, V. Giner, M. Paesmans, J. Klastersky, J. P. Sculier (Bruxelles, Charleroi, Belgium; Lille, France; Athens, Greece; Valence, Spain). A new TNM classification is better than ISS at predicting survival in stage III unresectable non-small cell lung cancer (NSCLC). A study by the European lung cancer working party (ELCWP). Eur Respir J 2003; 22: Suppl. 45, 1076
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: